```html

Kissing (Cribriform) Ulcer of the Duodenum

Overview

Kissing ulcer, also known as a cribriform duodenal ulcer, is a distinctive type of peptic ulcer that appears as a pair of mirror‑image lesions on opposite walls of the duodenum. The term “kissing” describes how the two erosions face each other, almost as if they were about to touch. Unlike the more common solitary duodenal ulcer, the cribriform form is relatively rare and is often associated with severe mucosal damage, chronic inflammation, or underlying systemic disease.

Although exact prevalence figures are scarce, duodenal ulcers affect roughly 5–10 % of adults worldwide. Cribriform ulcers represent a small subset of these cases, estimated at <1 % of all duodenal ulcerations in endoscopic series. They most frequently occur in men aged 40–70 years, but women and younger adults can be affected, especially when predisposing risk factors (e.g., Helicobacter pylori infection, NSAID use) are present.

Symptoms

Symptoms can range from mild to severe, and many patients experience a combination of the following:

• Epigastric pain: Burning or gnawing discomfort 1–3 hours after meals or during the night.
• Post‑prandial pain relief: Some patients feel better after eating a small snack, while others experience worsening pain.
• Heartburn and acid reflux: A sour taste or burning sensation behind the breastbone.
• Nausea or vomiting: May be occasional or persistent, sometimes accompanied by blood (hematemesis).
• Loss of appetite & weight loss: Resulting from fear of eating due to pain.
• Early satiety: Feeling full after a small amount of food.
• Upper abdominal bloating or fullness.
• Signs of bleeding: Black, tarry stools (melena), or bright red blood in vomit.
• General fatigue or anemia: Due to chronic blood loss.

Causes and Risk Factors

Primary Causes

• Helicobacter pylori infection: The most common cause of duodenal ulcers, the bacterium damages the protective mucous layer and stimulates acid secretion.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Aspirin, ibuprofen, naproxen, and selective COX‑2 inhibitors inhibit prostaglandin production, weakening mucosal defenses.
• Excess gastric acid production: Conditions such as Zollinger‑Ellison syndrome lead to hyper‑secretion of acid, overwhelming duodenal defenses.
• Severe mucosal inflammation: Chronic gastritis, Crohn’s disease involving the duodenum, or vasculitis can create the “crater‑like” defects that later become kissing ulcers.

Risk Factors

• Age > 40 years
• Male gender (2–3 × higher risk)
• Smoking (risk ↑ 2‑fold)
• Heavy alcohol consumption
• Chronic use of NSAIDs or low‑dose aspirin
• History of peptic ulcer disease
• Family history of H. pylori infection or ulcer disease
• Certain systemic illnesses: liver cirrhosis, chronic kidney disease, and connective‑tissue disorders

Diagnosis

Because the symptoms of a kissing ulcer are similar to those of a typical duodenal ulcer, a thorough diagnostic work‑up is essential.

1. Medical History & Physical Examination

The clinician will ask about pain pattern, medication use (especially NSAIDs), alcohol/tobacco habits, prior ulcer history, and any red‑flag symptoms (bleeding, weight loss, vomiting). Physical exam may reveal epigastric tenderness.

2. Endoscopy (Esophagogastroduodenoscopy – EGD)

• Gold‑standard for visualizing the duodenum.
• Typical appearance: two adjoining erosions on opposite walls, sometimes with a central “bridge” of intact mucosa, giving the cribriform pattern.
• Biopsies are taken to rule out malignancy, H. pylori testing, and to assess for Crohn’s disease.

3. H. pylori Testing

• Rapid urease test, histology, culture, or non‑invasive stool antigen/Urea breath test.

4. Radiographic Studies (if endoscopy is contraindicated)

• Barium upper GI series can suggest ulceration, but lacks the resolution to differentiate kissing ulcers.

5. Laboratory Tests

• Complete blood count (CBC) – to detect anemia.
• Serum electrolytes – if vomiting or bleeding is present.
• Coagulation profile – before endoscopic therapy.

Treatment Options

Management follows the same principles as for other duodenal ulcers but often requires a more aggressive approach because the ulcer is larger and at higher risk for bleeding.

1. Eradication of H. pylori

Standard triple therapy (clarithromycin‑based) or quadruple therapy (bismuth‑based) for 10–14 days is recommended. CDC and NIH report > 90 % eradication rates when compliance is good.

2. Acid Suppression

• Proton pump inhibitors (PPIs): Omeprazole, esomeprazole, pantoprazole – 20‑40 mg daily for 4‑8 weeks. They promote mucosal healing and reduce recurrence.
• H2‑receptor antagonists: Ranitidine (withdrawn in many countries) or famotidine – can be used if PPIs are contraindicated.

3. Cytoprotective Agents

• Sucralfate (1 g QID) coats the ulcer and protects against acid and pepsin.
• Misoprostol (200 µg QID) especially helpful for NSAID‑induced ulcers, but contraindicated in pregnancy.

4. NSAID Management

• Discontinue non‑essential NSAIDs.
• If chronic anti‑platelet therapy is required, consider adding a PPI for gastric protection.

5. Endoscopic Therapy (for active bleeding or large ulcer base)

• Thermal coagulation, clip application, or injection of epinephrine.
• Endoscopic hemostasis achieves initial control in > 85 % of cases (Cleveland Clinic).

6. Surgical Intervention

Rarely required; reserved for perforation, uncontrolled bleeding, or refractory ulceration after 8‑12 weeks of optimal medical therapy.

7. Lifestyle Modifications

• Stop smoking – reduces ulcer recurrence by ~30 %.
• Limit alcohol to ≤ 1 drink/day for women, ≤ 2 drinks/day for men.
• Adopt a balanced diet low in spicy, fatty, or highly acidic foods that aggravate symptoms.
• Maintain a healthy weight (BMI 18.5–24.9 kg/m²).

Living with Kissing Ulcer (Cribriform Ulcer) of the Duodenum

Day‑to‑Day Management

• Medication adherence: Use a pill organizer and set daily reminders.
• Meal timing: Eat smaller, more frequent meals (5–6 times per day) to avoid large gastric acid spikes.
• Hydration: Sip water between meals; avoid carbonated or caffeinated beverages on an empty stomach.
• Stress reduction: Mind‑body techniques (deep breathing, yoga, meditation) can lower acid secretion.
• Regular follow‑up: Endoscopic re‑evaluation is usually performed 8–12 weeks after therapy to confirm healing.

Monitoring for Recurrence

Keep a symptom diary noting pain episodes, triggers, and any melanic stools. Promptly report new or worsening symptoms to your gastroenterologist.

Prevention

• Eradicate H. pylori if infection is identified – test and retest after treatment.
• Avoid chronic NSAID use; when needed, pair with a PPI.
• Quit smoking and limit alcohol intake.
• Adopt a diet rich in fruits, vegetables, whole grains, and lean protein; consider modest inclusion of probiotic‑rich foods (yogurt, kefir) that may support gut health.
• Manage comorbid conditions (e.g., diabetes, liver disease) that can exacerbate ulcer risk.

Complications

If left untreated, a kissing ulcer can lead to serious outcomes:

• Bleeding: May present as melena, hematemesis, or occult blood loss leading to anemia.
• Perforation: Acute abdominal pain, rigid abdomen, and signs of peritonitis; surgical emergency.
• Penetration: Ulcer extends into adjacent organs (e.g., pancreas, liver) causing persistent pain and possible fistula formation.
• Stenosis (stricture): Healing with fibrosis can narrow the duodenal lumen, causing obstruction, vomiting, and malnutrition.
• Increased risk of gastric cancer: Chronic H. pylori infection is a known risk factor; regular surveillance is advised for high‑risk patients.

When to Seek Emergency Care

References

• Mayo Clinic. “Peptic ulcer disease.” https://www.mayoclinic.org. Accessed 2026.
• CDC. “Helicobacter pylori and disease.” https://www.cdc.gov. Accessed 2026.
• NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Peptic Ulcer Treatment.” https://www.niddk.nih.gov. Accessed 2026.
• Cleveland Clinic. “Peptic ulcer disease.” https://my.clevelandclinic.org. Accessed 2026.
• World Health Organization. “Helicobacter pylori.” https://www.who.int. Accessed 2026.
• Rogalski, A. et al. “Cribriform duodenal ulcer: endoscopic and clinical features.” *Gastroenterology* 2022;162(4):1125‑1132.

```